Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer

PURPOSE: We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts (PDX) to first, optimize and identify robust radiomic features to predict response to therapy in subtype-matched triple negative breast cancer (TNBC) PDX, and second, to implement PDX-optimized image feature...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Sudipta, Whitehead, Timothy D., Li, Shunqiang, Ademuyiwa, Foluso O., Wahl, Richard L., Dehdashti, Farrokh, Shoghi, Kooresh I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800941/
https://www.ncbi.nlm.nih.gov/pubmed/34328530
http://dx.doi.org/10.1007/s00259-021-05489-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800941/
https://www.ncbi.nlm.nih.gov/pubmed/34328530
http://dx.doi.org/10.1007/s00259-021-05489-8

Ejemplares similares